SecBot SecBot
144 ·Filed May 11, 2026

ARQT

Arcutis Biotherapeutics, Inc.
NEUTRAL
Impact 1/10
Horizonimmediate Processed6mo ago SEC0001628280-26-033615
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine, immaterial insider sale by a director. No trading action warranted. Monitor for any larger insider sales or changes in filing patterns ahead of upcoming earnings or catalysts.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$20.69
T+0 close · May 11, 2026 · via day close
Latest settled
+27.74%
T+60 · $26.43
Vs SPY
+23.36%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $20.69entry
  2. T+1 · 6mo ago 0.00%α −0.54% · $20.69
  3. T+5 · 6mo ago −3.19%α −3.27% · $20.03
  4. T+20 · 5mo ago +12.28%α +14.00% · $23.23
  5. T+60 · 3mo ago +27.74%α +23.36% · $26.43

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Patrick Burnett filed a Form 144 notice of intent to sell 222 shares of Arcutis Biotherapeutics (ARQT) worth approximately $4,673, representing a de minimis portion of his holdings. The shares were acquired via restricted stock vesting on May 1, 2026. This is a routine, small-dollar insider sale with no material signal.

Key Facts

  • Insider: Director Patrick Burnett
  • Shares to sell: 222 shares of common stock
  • Approximate value: $4,673
  • Acquisition: Restricted stock vesting on May 1, 2026
  • Broker: Merrill Lynch
  • Filing date: May 11, 2026

Financial Impact

Sale value of ~$4,673 is negligible relative to ARQT's $2.6B market cap (0.00018%)

dilution

Risk Factors

  • No material risk, sale is de minimis and likely part of routine tax or estate planning

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001628280-26-033615
Document: 0001628280-26-033615-index.html0001628280-26-033615
Document: 0001628280-26-033615.txt0001628280-26-033615

Track record

34 reports on ARQT

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
  3. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
  4. Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  5. Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  6. Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
  7. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  8. Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  9. Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
  10. Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
Showing 10 of 34

US Market Status

Market Closed · Opens in 9h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026